Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes.
| trading_symbol | registrant_name | time | price | change | percentage_change | 
|---|---|---|---|---|---|
| EBS | Emergent BioSolutions Inc. | 2025-10-30 20:00:59 | 12.81 | -0.03 | -0.23 | 
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time | 
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EBS | 0001367644 | Emergent BioSolutions Inc. | US29089Q1058 | 549300YW6TUOX8BE5103 | 141902018 | NYSE | 2834 | Pharmaceutical Preparations | 1231 | DE | 300 PROFESSIONAL DR | GAITHERSBURG | MD | 20879 | UNITED STATES | US | 240-631-3200 | 300 PROFESSIONAL DR, GAITHERSBURG, MD, 20879 | 300 PROFESSIONAL DR, GAITHERSBURG, MD, 20879 | — | — | 1998-09-05 | Joseph C. Papa | 1,600 | http://emergentbiosolutions.com | 360,700,000 | 60,600,000 | 52,519,964 | Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes. | 2025-10-30 15:11:50 | 
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding | 
|---|---|---|---|---|---|---|
| 2024 | 360,700,000 | -20,000,000 | -5.2535 | 54,337,026 | 2,133,593 | 4.0871 | 
| 2023 | 380,700,000 | -1,119,300,000 | -74.62 | 52,203,433 | 2,063,275 | 4.115 | 
| 2022 | 1,500,000,000 | -1,900,000,000 | -55.8824 | 50,140,158 | -361,263 | -0.7154 | 
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation | 
|---|---|---|---|---|---|---|---|---|
| Richard Lindahl | Chief Financial Officer, Treasurer, Executive Vice President | 2024 | 638,185 | 799,506 | 135,000 | 541,104 | 10,350 | 2,311,320 | 
| Coleen Glessner | Executive Vice President | 2024 | 602,139 | 747,521 | 0 | 507,192 | 9,186 | 2,053,213 | 
| Joseph Papa | Chief Executive Officer, President, Director | 2024 | 800,000 | 1,000,000 | 516,000 | 1,566,474 | 7,038 | 5,862,562 | 
| Haywood Miller | Chief Executive Officer | 2024 | 218,750 | 0 | 0 | 0 | 0 | 218,750 | 
| Paul Williams | Senior Vice President | 2024 | 469,560 | 685,001 | 0 | 325,882 | 8,069 | 1,675,687 | 
| Fiscal Year | Employee Count | 
|---|---|
| 2024 | 900 | 
| 2023 | 1,600 | 
| 2022 | 2,500 | 
| Fiscal Year | 2024 | 2023 | 2022 | 
|---|---|---|---|
| Revenue | 1,043,600,000 | 1,049,300,000 | 1,120,900,000 | 
| Cost Of Revenue | 185,900,000 | 705,400,000 | 693,700,000 | 
| Gross Profit | 213,000,000 | 317,600,000 | 385,800,000 | 
| Research And Development Expenses | 70,700,000 | 111,400,000 | 193,000,000 | 
| General And Administrative Expenses | 308,000,000 | 368,400,000 | 340,300,000 | 
| Operating Expenses | — | — | — | 
| Operating Income | -108,700,000 | -726,400,000 | -172,700,000 | 
| Net Income | -190,600,000 | -760,500,000 | -223,800,000 | 
| Earnings Per Share Basic | -3.6 | -14.85 | -4.47 | 
| Earnings Per Share Diluted | -3.6 | -14.85 | -4.47 | 
| Weighted Average Shares Outstanding Basic | 53,000,000 | 51,200,000 | 50,100,000 | 
| Weighted Average Shares Outstanding Diluted | 53,000,000 | 51,200,000 | 50,100,000 | 
| Fiscal Year | 2024 | 2023 | 2022 | 
|---|---|---|---|
| Cash And Cash Equivalents | 99,500,000 | 111,700,000 | 642,600,000 | 
| Marketable Securities Current | — | — | — | 
| Accounts Receivable | 154,500,000 | 191,000,000 | 158,400,000 | 
| Inventories | 311,700,000 | 328,900,000 | 351,800,000 | 
| Non Trade Receivables | — | — | — | 
| Other Assets Current | — | — | — | 
| Total Assets Current | 598,700,000 | 679,500,000 | 1,210,700,000 | 
| Marketable Securities Non Current | — | — | — | 
| Property Plant And Equipment | 270,600,000 | 382,800,000 | 817,600,000 | 
| Other Assets Non Current | 18,900,000 | 194,300,000 | 191,300,000 | 
| Total Assets Non Current | 275,200,000 | 392,400,000 | 826,700,000 | 
| Total Assets | 1,389,700,000 | 1,823,200,000 | 3,166,600,000 | 
| Accounts Payable | 60,900,000 | 112,200,000 | 103,500,000 | 
| Deferred Revenue | 4,800,000 | 27,200,000 | 26,400,000 | 
| Short Term Debt | 0 | 413,700,000 | 957,300,000 | 
| Other Liabilities Current | 27,700,000 | 32,700,000 | 45,900,000 | 
| Total Liabilities Current | 162,400,000 | 651,300,000 | 1,229,900,000 | 
| Long Term Debt | 700,000,000 | 868,400,000 | 1,413,800,000 | 
| Other Liabilities Non Current | 39,100,000 | 28,900,000 | 33,400,000 | 
| Total Liabilities Non Current | 744,500,000 | 522,600,000 | 553,700,000 | 
| Total Liabilities | 906,900,000 | 1,173,900,000 | 1,783,600,000 | 
| Common Stock | 100,000 | 100,000 | 100,000 | 
| Retained Earnings | -212,400,000 | -21,800,000 | 734,000,000 | 
| Accumulated Other Comprehensive Income | -5,200,000 | -5,700,000 | 3,100,000 | 
| Total Shareholders Equity | 482,800,000 | 649,300,000 | 1,383,000,000 | 
| Fiscal Year | 2024 | 2023 | 2022 | 
|---|---|---|---|
| Depreciation And Amortization | 108,800,000 | 125,100,000 | 83,400,000 | 
| Share Based Compensation Expense | 18,000,000 | 23,100,000 | 45,100,000 | 
| Other Non Cash Income Expense | -6,500,000 | -13,000,000 | -6,400,000 | 
| Change In Accounts Receivable | 24,400,000 | 21,600,000 | -114,700,000 | 
| Change In Inventories | 24,500,000 | -600,000 | 51,900,000 | 
| Change In Non Trade Receivables | — | — | — | 
| Change In Other Assets | — | — | — | 
| Change In Accounts Payable | -33,000,000 | 10,600,000 | -14,000,000 | 
| Change In Other Liabilities | 12,300,000 | -55,700,000 | -66,700,000 | 
| Cash From Operating Activities | 58,700,000 | -206,300,000 | -34,100,000 | 
| Purchases Of Marketable Securities | — | — | — | 
| Sales Of Marketable Securities | — | — | — | 
| Acquisition Of Property Plant And Equipment | 22,900,000 | 51,600,000 | 115,800,000 | 
| Acquisition Of Business | — | — | — | 
| Other Investing Activities | — | — | — | 
| Cash From Investing Activities | 125,200,000 | 212,300,000 | -381,300,000 | 
| Tax Withholding For Share Based Compensation | 1,200,000 | 2,500,000 | 5,900,000 | 
| Payments Of Dividends | — | — | — | 
| Issuance Of Common Stock | 0 | 8,400,000 | — | 
| Repurchase Of Common Stock | 0 | 0 | 75,500,000 | 
| Issuance Of Long Term Debt | 65,000,000 | 20,000,000 | 598,000,000 | 
| Repayment Of Long Term Debt | 284,200,000 | 398,800,000 | 0 | 
| Other Financing Activities | 1,500,000 | 1,800,000 | 5,000,000 | 
| Cash From Financing Activities | -190,000,000 | -535,700,000 | 481,200,000 | 
| Change In Cash | -6,100,000 | -530,900,000 | 66,300,000 | 
| Cash At End Of Period | 99,500,000 | 111,700,000 | 642,600,000 | 
| Income Taxes Paid | 26,500,000 | 52,800,000 | 6,200,000 | 
| Interest Paid | 64,000,000 | 68,300,000 | 33,000,000 | 
| Fiscal Year | 2024 | 2023 | 2022 | 
|---|---|---|---|
| Earnings Per Share | -3.6 | -14.85 | -4.47 | 
| Price To Earnings Ratio | -2.6556 | -0.1616 | -2.6421 | 
| Earnings Growth Rate | -75.7576 | 232.2148 | -203.4722 | 
| Price Earnings To Growth Ratio | 0.0351 | -0.0007 | 0.013 | 
| Book Value Per Share | 9.1094 | 12.6816 | 27.6048 | 
| Price To Book Ratio | 1.0495 | 0.1892 | 0.4278 | 
| Ebitda | 15,700,000 | -494,700,000 | -96,900,000 | 
| Enterprise Value | 1,107,180,000 | 1,293,280,000 | 2,320,181,000 | 
| Dividend Yield | — | — | — | 
| Dividend Payout Ratio | — | — | — | 
| Debt To Equity Ratio | 1.4499 | 1.9746 | 1.7145 | 
| Capital Expenditures | -3,400,000 | -309,700,000 | 100,900,000 | 
| Free Cash Flow | 62,100,000 | 103,400,000 | -135,000,000 | 
| Return On Equity | -0.3948 | -1.1713 | -0.1618 | 
| One Year Beta | 3.5773 | 2.1673 | 1.4512 | 
| Three Year Beta | 1.9504 | 1.5001 | 1.1999 | 
| Five Year Beta | 1.4416 | 1.2498 | 1.1688 | 
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction | 
|---|---|---|---|---|---|
| LINDAHL RICHARD S | EVP, Chief Financial Officer | 2025-10-15 | 4,995 | D | 291,497 | 
| Glessner Coleen | EVP, Quality & Ethics, and CPL | 2025-10-07 | 30,608 | D | 144,319 | 
| Zoon Kathryn C | Director | 2025-08-15 | 7,086 | D | 71,799 | 
| DeGolyer Donald W | Director | 2025-08-12 | 7,844 | D | 137,659 | 
| Hartzel William | SVP, Bioservices | 2025-07-11 | 4,263 | D | 103,692 | 
| Name Of Reporting Person | Report Date | State | Transaction Type | Transaction Date | Owner Type | Amount | 
|---|---|---|---|---|---|---|
| Steve Cohen | 2025-01-10 | TN09 | Sale | 2024-12-11 | — | $1,001 - $15,000 | 
| Josh Gottheimer | 2021-12-13 | NJ05 | Sale | 2021-11-05 | Joint | $1,001 - $15,000 | 
| Steve Cohen | 2019-09-12 | TN09 | Sale | 2019-08-29 | — | $15,001 - $50,000 | 
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security | 
|---|---|---|---|---|
| STRS OHIO | 2025-09-30 | 115,542 | 13,100 | 8.82 | 
| Covestor Ltd | 2025-09-30 | 35,000 | 4,011 | 8.726 | 
| Avidian Wealth Enterprises, LLC | 2025-09-30 | 92,081 | 10,440 | 8.82 | 
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | 2025-09-30 | 112,999 | 11,391 | 9.92 | 
| AMALGAMATED BANK | 2025-09-30 | 16,000 | 1,843 | 8.6815 | 
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets | 
|---|---|---|---|---|---|---|
| SEI INSTITUTIONAL INVESTMENTS TRUST | 2025-08-31 | SIIT Small Cap II Fund - Class A | SECAX | 18,790 | 155,957 | 0.064 | 
| SEI INSTITUTIONAL INVESTMENTS TRUST | 2025-08-31 | SIIT SMALL CAP FUND - CLASS A | SLPAX | 16,410 | 136,203 | 0.0718 | 
| SEI INSTITUTIONAL INVESTMENTS TRUST | 2025-08-31 | SIIT Extended Market Index Fund - Class A | SMXAX | 8,000 | 66,400 | 0.0055 | 
| RBB FUND, INC. | 2025-08-31 | Motley Fool Next Index ETF | TMFX | 875 | 7,262.5 | 0.0219 | 
| RBB Fund Trust | 2025-08-31 | Longview Advantage ETF | EBI | 79 | 655.7 | 0.0001 |